Novavax Inc. ($NVAX) Stock Forecast: Down 7.0% Today

What is Novavax Inc.?

Novavax Inc. (NVAX) is a biotechnology company focused on developing vaccines for infectious diseases, including their COVID-19 vaccine candidate.

Why is Novavax Inc. going down?

NVAX stock is down 7.0% on Apr 29, 2025 13:42

• The bearish movement in NVAX stock today could be attributed to the request for new trials for Novavax's COVID vaccine by former FDA appointees, possibly causing a delay in approval.
• Despite the recent positive developments and surge in NVAX stock price, uncertainty around the new clinical trials request may have unsettled investors, resulting in the downward trend.
• Investors seem wary of the potential consequences of a delayed approval and its effects on Novavax's competitiveness in the COVID-19 vaccine market, adding to the stock's downward pressure.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )

The President Donald Trump administration's request for Novavax Inc. NVAX to conduct new clinical trials for its COVID-19 vaccine.

https://www.benzinga.com/general/health-care/25/04/45059756/trump-era-fda-appointees-request-new-trials-for-novavax-covid-vaccine-reportedly-delaying-app

Novavax ( NVAX ) Surges 19.5%: Is This an Indication of Further Gains?

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

https://www.zacks.com/stock/news/2454347/novavax-nvax-surges-195-is-this-an-indication-of-further-gains

Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps - Novavax ( NASDAQ:NVAX )

Novavax says its COVID-19 vaccine BLA is approvable and awaits FDA response after a post-marketing data request. SHIELD-Utah study shows Novavax's JN.1 vaccine had milder side effects than Pfizer-BioNTech's 2024-2025 mRNA shot. Markets are messy-but the right setups can still deliver ...

https://www.benzinga.com/general/biotech/25/04/44966369/novavaxs-covid-19-vaccine-nears-fda-full-approval-stock-jumps

Trending Today

Copper ($COPPER) Commodity Forecast: Down 6.1% Today

Floki ($FLOKI) Crypto Forecast: Up 6.1% Today

Sei ($SEI) Crypto Forecast: Down 5.1% Today

Bittensor ($TAO) Crypto Forecast: Down 5.4% Today

Optimism ($OP) Crypto Forecast: Down 5.0% Today

Wormhole ($W) Crypto Forecast: Down 5.2% Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 5.4% Today

Internet Computer ($ICP) Crypto Forecast: Down 5.2% Today

Starknet ($STRK) Crypto Forecast: Down 5.0% Today

Ondo ($ONDO) Crypto Forecast: Down 5.2% Today

Novavax Inc. Price History

01.03.2025 - NVAX Stock was down 6.0%

• NVAX stock dipped more than the broader market, closing at $7.26, marking a -1.76% move from the prior day.
• Biotech stocks, including Novavax, fell after a top FDA official resigned due to irreconcilable differences with the new HHS Secretary, causing uncertainty in the sector.
• Reports about the Trump administration planning to cease financial support for vaccine alliance Gavi and scale back efforts to combat malaria added to the negative sentiment surrounding biotech stocks like Novavax.
• The combination of internal FDA issues and external government funding concerns likely contributed to the bearish movement in NVAX stock today.

23.03.2025 - NVAX Stock was up 19.5%

• Despite a market dip, Novavax (NVAX) managed to gain, showcasing its resilience and potential strength in the market.
• The positive movement in Novavax's stock could be attributed to potential positive news regarding its vaccine development or progress in clinical trials.
• Investors might be optimistic about Novavax's future prospects, leading to increased buying activity and driving the stock price higher.
• This divergence from the overall market trend suggests that investors have confidence in Novavax's ability to deliver results and make significant advancements in the healthcare sector.

11.03.2025 - NVAX Stock was up 13.2%

• The bullish movement in NVAX stock could be attributed to the positive market sentiment driven by the company's recent jump in share price and optimistic earnings estimate revisions.
• Despite concerns raised by the HHS Secretary regarding the efficacy of Novavax's COVID-19 vaccine, investors seem to be focusing on the potential strength and upside in the stock.
• The market might be interpreting the concerns as an opportunity for Novavax to address any issues and improve its vaccine, leading to increased confidence in the company's future prospects.
• The overall positive trend in NVAX stock reflects investor confidence in the company's ability to navigate challenges and capitalize on opportunities in the biotechnology sector.

28.02.2025 - NVAX Stock was down 5.1%

• Novavax (NVAX) experienced a bearish movement likely due to profit-taking after a recent uptrend.
• Negative news surrounding plans to reduce financial support for vaccine efforts may have added to the selling pressure on Novavax shares.
• Investors may be concerned about the potential impact on Novavax's vaccine development and revenue streams, leading to the stock's decline.
• The broader market sentiment, combined with specific news related to vaccine funding, likely contributed to Novavax's bearish movement today.

24.03.2025 - NVAX Stock was down 6.3%

• Despite positive updates on Novavax's COVID-19 vaccine progress towards FDA approval and its lower incidence of side effects relative to rivals, the stock trended bearishly.
• Following a recent spike in share value, profit-taking actions by investors might have contributed to today's downturn.
• While Novavax closed slightly above the previous day's numbers, the broader market decline likely played a role in the stock's bearish performance.

25.01.2025 - NVAX Stock was down 6.0%

• NVAX stock experienced a bearish movement despite the anticipation of a new coronavirus triggering another pandemic, which usually boosts vaccine stocks.
• Investors may have had high expectations for NVAX's fourth-quarter earnings call, focusing on updates on its pipeline, and any disappointments or lack of positive updates could have led to the bearish movement.
• The overall market sentiment towards biotech stocks this earnings season may have influenced NVAX's performance, as investors assess the industry's outlook based on the upcoming earnings reports of various biotech companies.

16.03.2025 - NVAX Stock was down 5.6%

• Novavax's stock fell more than the broader market, closing at $6.39 with a -0.31% move from the previous day.
• A study revealed that Novavax's Covid vaccine showed milder side effects compared to Pfizer-BioNTech's shot, which could have impacted market sentiment.
• The stock took a hit as the HHS Secretary raised concerns about the efficacy of Novavax's protein-based Covid-19 vaccine in a recent interview.
• The combination of market factors such as comparative vaccine side effects and regulatory concerns likely contributed to the bearish movement in Novavax's stock today. Investors may be reacting to the perceived challenges facing the company in the competitive vaccine landscape.

27.01.2025 - NVAX Stock was down 8.7%

• Despite reporting a narrower Q4 loss and sales surpassing expectations, Novavax saw a decline in its stock value.
• Investor concerns may have arisen due to the company's strategic shift towards enhancing value rather than solely focusing on commercializing the COVID-19 vaccine.
• The surge in vaccine stocks, including NVAX, following the news of a new coronavirus discovered by Chinese scientists might have prompted profit-taking actions by investors, leading to the stock's decline.
• The market's response could also be linked to uncertainties surrounding Novavax's upcoming earnings report, with investors eagerly anticipating insights into the company's financial outlook.

27.01.2025 - NVAX Stock was up 6.2%

• A recent financial update from Novavax highlighted a reduced loss in Q4 and a strategic shift towards maximizing value rather than focusing solely on commercializing the COVID-19 vaccine, instilling confidence among investors in the company's long-term plan.
• The release of a positive earnings report, revealing sales of $88.31 million and an EPS loss in line with expectations, has contributed to the upward trend of NVAX stock.
• Investor interest in Novavax has been piqued by the company's projected adjusted revenue of $300-$350 million for 2025, indicating optimism about its future performance.
• The broader uptrend in vaccine stocks, including NVAX, following the identification of a new coronavirus strain in China, has further bolstered the positive outlook on the company's prospects and its potential in addressing future pandemics.

10.03.2025 - NVAX Stock was down 16.7%

• Despite positive earnings estimates and increased trading volume, Novavax (NVAX) faced significant bearish movement today.
• The recent surge in share price and optimistic future outlook may have prompted profit-taking among investors, contributing to the bearish trend.
• Concerns over potential delays in vaccine development or regulatory obstacles may have triggered a sell-off of NVAX shares.
• Shifting market sentiment towards healthcare and biotech sectors could have adversely impacted NVAX's performance, despite favorable developments for the company.

07.03.2025 - NVAX Stock was up 5.7%

• NVAX stock gained 11.4% today.
• The positive movement in earnings estimate revisions for the company suggests potential future strength.
• Despite a delay in the FDA's decision on full approval of Novavax's COVID-19 vaccine, investor sentiment remained positive, focusing on the company's overall performance and potential.
• The resignation of a top FDA official, causing a decline in biotech stocks, did not have a lasting negative impact on NVAX, indicating investor confidence in the company's prospects amid broader industry concerns.

29.03.2025 - NVAX Stock was down 7.0%

• The bearish movement in NVAX stock today could be attributed to the request for new trials for Novavax's COVID vaccine by former FDA appointees, possibly causing a delay in approval.
• Despite the recent positive developments and surge in NVAX stock price, uncertainty around the new clinical trials request may have unsettled investors, resulting in the downward trend.
• Investors seem wary of the potential consequences of a delayed approval and its effects on Novavax's competitiveness in the COVID-19 vaccine market, adding to the stock's downward pressure.